Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI

Harald Renz; Claus Bachert; Claudia Berek; Eckard Hamelmann; Francesca Levi-Schaffer; Ulrike Raap; Hans Uwe Simon; Sabine Ploetz; Christian Taube; Peter Valent; David Voehringer; Thomas Werfel; Nan Zhang; Johannes Ring

doi:10.1111/sji.13032

Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI

Harald Renz^*, Claus Bachert, Claudia Berek, Eckard Hamelmann, Francesca Levi-Schaffer, Ulrike Raap, Hans Uwe Simon, Sabine Ploetz, Christian Taube, Peter Valent, David Voehringer, Thomas Werfel, Nan Zhang, Johannes Ring

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Over the last century, eosinophils have been regarded ambiguously either as ‘friends’ or ‘foes’. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.

Original language	American English
Article number	e13032
Journal	Scandinavian Journal of Immunology
Volume	93
Issue number	6
DOIs	https://doi.org/10.1111/sji.13032
State	Published - Jun 2021

Bibliographical note

Funding Information:
Harald Renz was funded by the Universities Giessen Marburg Lung Center and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. Claus Bachert was supported by grants from the European Commission?s Seventh Framework Program under grant agreement No. 260895 (PREDICTA), the Flemish Scientific Research Board (Research Foundation-Flanders, projects 1841713N, G.039412N, G.067512N, and BOF14/GOA/019), and the Interuniversity Attraction Poles Program of the Belgian State Science Policy Office (No. IAP P7/30) (C.B.); The study was supported in part by the Austrian Science Fund (FWF) grant SFB F47-B20 to Peter Valent. Eckard Hamelmann was funded by the German Ministry of Education and Research (BMBF: 01GL1742D CHAMP). David Voehringer was funded by the DFG grant Vo944/9-1 to D.V. Ulrike Raap was funded by the DFG RA 1026 3-1. Johannes Ring and Sabine Ploetz were supported by the Christine Kuehne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland. Thomas Werfel was funded by Hanover Medical University, by the DFG cluster of excellence RESIST and by DFG grant WeXXX. Open Access funding enabled and organized by Projekt DEAL.WOA Institution: PHILIPPS-UNIVERSITAET MARBURGBlended DEAL: Projekt DEAL.

Publisher Copyright:
© 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.

Keywords

DNAzyme against GATA3; eosinophil
anti-interleukin 5
eosinophil diseases
hypereosinophilic syndrome
anti&#8208
interleukin 5
DNAzyme against GATA3
eosinophil

Access to Document

10.1111/sji.13032

Cite this

Renz, H., Bachert, C., Berek, C., Hamelmann, E., Levi-Schaffer, F., Raap, U., Simon, H. U., Ploetz, S., Taube, C., Valent, P., Voehringer, D., Werfel, T., Zhang, N., & Ring, J. (2021). Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI. Scandinavian Journal of Immunology, 93(6), Article e13032. https://doi.org/10.1111/sji.13032

@article{564e8b3932d04690aa839d4552615591,

title = "Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI",

abstract = "Over the last century, eosinophils have been regarded ambiguously either as {\textquoteleft}friends{\textquoteright} or {\textquoteleft}foes{\textquoteright}. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.",

keywords = "DNAzyme against GATA3; eosinophil, anti-interleukin 5, eosinophil diseases, hypereosinophilic syndrome, anti&#8208, interleukin 5, DNAzyme against GATA3, eosinophil",

author = "Harald Renz and Claus Bachert and Claudia Berek and Eckard Hamelmann and Francesca Levi-Schaffer and Ulrike Raap and Simon, {Hans Uwe} and Sabine Ploetz and Christian Taube and Peter Valent and David Voehringer and Thomas Werfel and Nan Zhang and Johannes Ring",

note = "Funding Information: Harald Renz was funded by the Universities Giessen Marburg Lung Center and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. Claus Bachert was supported by grants from the European Commission?s Seventh Framework Program under grant agreement No. 260895 (PREDICTA), the Flemish Scientific Research Board (Research Foundation-Flanders, projects 1841713N, G.039412N, G.067512N, and BOF14/GOA/019), and the Interuniversity Attraction Poles Program of the Belgian State Science Policy Office (No. IAP P7/30) (C.B.); The study was supported in part by the Austrian Science Fund (FWF) grant SFB F47-B20 to Peter Valent. Eckard Hamelmann was funded by the German Ministry of Education and Research (BMBF: 01GL1742D CHAMP). David Voehringer was funded by the DFG grant Vo944/9-1 to D.V. Ulrike Raap was funded by the DFG RA 1026 3-1. Johannes Ring and Sabine Ploetz were supported by the Christine Kuehne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland. Thomas Werfel was funded by Hanover Medical University, by the DFG cluster of excellence RESIST and by DFG grant WeXXX. Open Access funding enabled and organized by Projekt DEAL.WOA Institution: PHILIPPS-UNIVERSITAET MARBURGBlended DEAL: Projekt DEAL. Publisher Copyright: {\textcopyright} 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.",

year = "2021",

month = jun,

doi = "10.1111/sji.13032",

language = "American English",

volume = "93",

journal = "Scandinavian Journal of Immunology",

issn = "0300-9475",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "6",

}

Renz, H, Bachert, C, Berek, C, Hamelmann, E, Levi-Schaffer, F, Raap, U, Simon, HU, Ploetz, S, Taube, C, Valent, P, Voehringer, D, Werfel, T, Zhang, N & Ring, J 2021, 'Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI', Scandinavian Journal of Immunology, vol. 93, no. 6, e13032. https://doi.org/10.1111/sji.13032

TY - JOUR

T1 - Physiology and pathology of eosinophils

T2 - Recent developments: Summary of the Focus Workshop Organized by DGAKI

AU - Renz, Harald

AU - Bachert, Claus

AU - Berek, Claudia

AU - Hamelmann, Eckard

AU - Levi-Schaffer, Francesca

AU - Raap, Ulrike

AU - Simon, Hans Uwe

AU - Ploetz, Sabine

AU - Taube, Christian

AU - Valent, Peter

AU - Voehringer, David

AU - Werfel, Thomas

AU - Zhang, Nan

AU - Ring, Johannes

N1 - Funding Information: Harald Renz was funded by the Universities Giessen Marburg Lung Center and the German Center for Lung Disease (DZL German Lung Center, no. 82DZL00502) for UGMLC. Claus Bachert was supported by grants from the European Commission?s Seventh Framework Program under grant agreement No. 260895 (PREDICTA), the Flemish Scientific Research Board (Research Foundation-Flanders, projects 1841713N, G.039412N, G.067512N, and BOF14/GOA/019), and the Interuniversity Attraction Poles Program of the Belgian State Science Policy Office (No. IAP P7/30) (C.B.); The study was supported in part by the Austrian Science Fund (FWF) grant SFB F47-B20 to Peter Valent. Eckard Hamelmann was funded by the German Ministry of Education and Research (BMBF: 01GL1742D CHAMP). David Voehringer was funded by the DFG grant Vo944/9-1 to D.V. Ulrike Raap was funded by the DFG RA 1026 3-1. Johannes Ring and Sabine Ploetz were supported by the Christine Kuehne Center for Allergy Research and Education (CK-CARE), Davos, Switzerland. Thomas Werfel was funded by Hanover Medical University, by the DFG cluster of excellence RESIST and by DFG grant WeXXX. Open Access funding enabled and organized by Projekt DEAL.WOA Institution: PHILIPPS-UNIVERSITAET MARBURGBlended DEAL: Projekt DEAL. Publisher Copyright: © 2021 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.

PY - 2021/6

Y1 - 2021/6

N2 - Over the last century, eosinophils have been regarded ambiguously either as ‘friends’ or ‘foes’. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.

AB - Over the last century, eosinophils have been regarded ambiguously either as ‘friends’ or ‘foes’. Recent developments have greatly enhanced our understanding of the role and function of eosinophils in health and disease. Pathogenic eosinophilic inflammation can lead to severe diseases in various organs, such as the gastrointestinal tract, airways, heart and skin. In a 2-day focus workshop of the German Society for Allergology and Clinical Immunology (DGAKI), the state of the art was discussed and practical recommendations for diagnosis and treatment of eosinophilic diseases, with a particular focus on new biologics, such as anti-interleukin 5 and anti-interleukin 5R, were derived.

KW - DNAzyme against GATA3; eosinophil

KW - anti-interleukin 5

KW - eosinophil diseases

KW - hypereosinophilic syndrome

KW - anti&#8208

KW - interleukin 5

KW - DNAzyme against GATA3

KW - eosinophil

UR - http://www.scopus.com/inward/record.url?scp=85102274780&partnerID=8YFLogxK

U2 - 10.1111/sji.13032

DO - 10.1111/sji.13032

M3 - Review article

C2 - 33624312

AN - SCOPUS:85102274780

SN - 0300-9475

VL - 93

JO - Scandinavian Journal of Immunology

JF - Scandinavian Journal of Immunology

IS - 6

M1 - e13032

ER -

Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKI

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this